Alnylam Pharmaceuticals, Inc. (ALNY)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:18 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow ALNY in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ALNY and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ALNY at a glance
Key statistics
$30.87B
Market capitalization
- Previous close
- $230.71
- Open
- $227.88
- Day range
- $225.08 – $230.64
- Volume
- 568.7K
- Average volume (30 sessions)
- 1.32M
- Shares outstanding
- 133.81M
- Price / earnings
- 38.2
- Earnings per share
- $6.04
- Price / book
- 22.8
- Price / sales
- 6.4
- Beta (1 year, vs SPY)
- 0.47
Where the price sits in its year
52-week range
10% of the range
- Below the 52-week high
- -54.3%
- Above the 52-week low
- +14.6%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $234.49-1.6%
- 50-day average
- $238.97-3.5%
- 200-day average
- $292.63-21.2%
Between the conventional 30 and 70 bands.
+3.1%
1 week
-5.6%
1 month
-13.6%
3 months
-42.0%
Year to date
-52.1%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ALNY
ALNY on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ALNY.
See the plans →
Every planScreen names like ALNY
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ALNY
Put ALNY on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ALNY
See whether there is an open premium alert on ALNY, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ALNY headlines
- Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
GlobeNewswire Inc. · Sep 15, 2026
- Tenaya Therapeutics Stock Jumps After New Alnylam Deal
Benzinga · Mar 5, 2026
- Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale
Benzinga · Jan 12, 2026
- What's Going On With Alnylam Stock On Friday?
Benzinga · Nov 28, 2025
- Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
GlobeNewswire Inc. · Aug 30, 2025
- Scenic Enters License and Research Agreement with Alnylam
GlobeNewswire Inc. · Aug 26, 2025
- Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
Benzinga · Aug 1, 2025
- Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast
Benzinga · Jul 31, 2025
SEC Form 4, most recent first
Insider filings
SUPRAN BRYAN
−1.8K
EVP, CLO and Secretary · Open-market sale
$398.86K · Oct 2, 2026
Greenstreet Yvonne
+107
Chief Executive Officer, Director · Grant or award
· Sep 19, 2026
PYOTT DAVID E I
−1.2K
Director · Open-market sale
$351.22K · Jun 1, 2026
PYOTT DAVID E I
−17
Director · Open-market sale
$5.15K · Jun 1, 2026
PYOTT DAVID E I
−3.8K
Director · Option exercise
· Jun 1, 2026
Cravatt Benjamin
+4.4K
Director · Grant or award
· Jun 1, 2026
PYOTT DAVID E I
+3.8K
Director · Option exercise
· Jun 1, 2026
PYOTT DAVID E I
−1.2K
Director · Open-market sale
$366.44K · Jun 1, 2026
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Cambridge, MA
- Employees
- 2,500
- Listed since
- May 28, 2004
- Website
- alnylam.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.